IGF‑1 DES (des(1-3) IGF‑I) · Preclinical Research Overview
Quickstart Highlights
Compound: IGF‑1 DES = des(1‑3) IGF‑I (N‑terminally truncated IGF‑1 analog)
What makes it different: Much lower binding to IGF binding proteins (IGFBPs) → tends to be more "bioavailable"/potent at the receptor level in experimental systems.
Evidence base for dosing: Primarily animal infusion studies and in‑vitro concentration work (no standardized, FDA‑recognized human protocol)
Core research theme: Anabolism / nitrogen retention, growth signaling, tissue‑response modeling
Dosing & Reconstitution
Standard Approach (Preclinical context)
Standard Approach
Important reality: For des(1‑3) IGF‑1, the clearest dosing in the peer‑reviewed record is from animal studies, commonly delivered via continuous infusion (osmotic minipump) rather than intermittent injections.
Examples of in‑vivo research dosing (rats):
- 0.9 mg/kg/day des(1‑3) IGF‑1 via osmotic minipump for 7 days (growth model in nephrectomized rats).
- ~1.08 mg/kg/day des(1‑3) IGF‑1 (reported in diabetic rat anabolic/nitrogen retention work).
- Another related rat protocol reports 1.2 mg/kg/day des(1‑3) IGF‑1 over 7 days.
In‑vitro concentration ranges (example):
- Experimental chamber studies used ~6.7–53 nM ranges when comparing IGF‑1 vs des(1‑3) IGF‑1 effects on insulin release dynamics.
Supplies Needed (Educational / Lab Context)
- Peptide vial (lyophilized)
- Sterile diluent per institutional SOP (sterile water/saline depending on assay)
- Sterile syringes / pipette tips (depending on whether preparing for in‑vivo models or in‑vitro assays)
- Cold storage setup (refrigerator/freezer) + light protection
Protocol Overview
Why protocols look the way they do: Many published in‑vivo protocols use continuous exposure (minipump infusion) to stabilize signaling and avoid peaks/troughs.
Common endpoints studied:
- Body weight change
- Nitrogen retention / protein synthesis
- Tissue‑specific response
- Metabolic readouts (context‑dependent)
Dosing Protocol (Research context)
Research Protocol (In‑Vivo) — Most Citable Structures
- A) Continuous infusion model (7 days): 0.9 mg/kg/day des(1‑3) IGF‑1 × 7 days (osmotic minipump).
- B) Higher infusion dosing used in anabolic/nitrogen retention experiments: ~1.08 mg/kg/day des(1‑3) IGF‑1 (rat model); 1.2 mg/kg/day des(1‑3) IGF‑1 × ~7 days (rat protocol).
Research Protocol (In‑Vitro) — Example Concentration Band: 6.7–53 nM used as a range in comparative experiments (IGF‑1 vs des(1‑3) IGF‑1).
What you should not present as "standardized": Any "mcg per day" human schedule — because that's generally derived from non‑clinical, non‑authoritative sources and is not a validated clinical protocol for des(1‑3) IGF‑1.
Storage Instructions
- Keep lyophilized material cold and protected from light
- After reconstitution, follow sterile handling timelines and stability guidance from your lab SOP
- Avoid repeated freeze–thaw cycles (aliquoting is commonly used in lab workflows)
Important Notes
- IGF‑1 DES (des(1‑3) IGF‑1) ≠ IGF‑1 LR3 ≠ recombinant human IGF‑1 (mecasermin). These differ in binding proteins, kinetics, and research use‑cases.
- Des(1‑3) IGF‑1 is often discussed as having reduced IGFBP binding, which can change distribution and clearance behavior.
- Not FDA‑approved as a therapeutic agent; dosing in literature is primarily preclinical.
How This Works
Des(1‑3) IGF‑1 is a truncated IGF‑1 analog designed/observed to:
- Retain affinity for IGF‑1 receptor (IGF‑1R)
- Interact differently with IGF binding proteins (IGFBPs), often described as lower binding, which can increase free fraction in experimental settings.
Benefits & Side Effects (Research Context)
Observed / Investigated Effects
- Increased weight gain and nitrogen retention in certain animal models under specific conditions
- Growth support in models with reduced renal mass (dose‑dependent protocols studied)
Safety Signals / Constraints
- Biodistribution work suggests rapid internalization/catabolism after receptor binding and fast clearance characteristics in certain setups.
- Human safety and dosing standardization: insufficient for protocol‑level claims (for IGF‑1 DES specifically).
Lifestyle Factors
In research discussions, outcomes are highly dependent on:
- Feeding status and protein intake (for nitrogen balance outcomes)
- Training/immobilization conditions (in muscle response models)
- Disease model selection (diabetes, renal mass reduction, injury models)
Administration models used in research
For this educational page, we do not include "how to inject" instructions for IGF‑1 DES, since the strongest literature protocols are animal infusion models (minipumps) and the compound lacks standardized human therapeutic use.
Research delivery methods: osmotic minipump (continuous infusion), local tissue delivery, or cell‑culture exposure — no standardized human injection protocol.
Recommended Source
For IGF‑1 analog research materials, the quality benchmarks you'd highlight are:
- Verified identity/purity analytics (independent COA where possible)
- Sterility/endotoxin controls when relevant to in‑vivo work
- Cold‑chain integrity
Important Note
This content is for educational purposes only and is not medical advice. IGF‑1 DES is for research use only. Not for human consumption. Always consult with qualified professionals before starting any peptide research protocol.
References
-
Rat anabolic/nitrogen retention dosing — including des(1‑3) IGF‑1 ~1.08 mg/kg/day
-
Nephrectomized rat model — des(1‑3) IGF‑1 0.9 mg/kg/day for 7 days
-
Des(1‑3) IGF‑1 additional rat dosing example — 1.2 mg/kg/day
-
In‑vitro concentration range example — 6.7–53 nM
-
Biodistribution/clearance considerations — for labeled des(1‑3) IGF‑1
